Association Between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan Before Hematopoietic Stem Cell Transplantation

@article{Ansari2014AssociationBB,
  title={Association Between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan Before Hematopoietic Stem Cell Transplantation},
  author={M. Ansari and Y. Th{\'e}{\^o}ret and M. A. Rezgui and C. Peters and S. Mezziani and C. Desjean and M. Vachon and M. Champagne and M. Duval and M. Krajinovic and H. Bittencourt},
  journal={Therapeutic Drug Monitoring},
  year={2014},
  volume={36},
  pages={93–99}
}
Background and Objective: Intravenous (IV) busulfan (Bu) combined with therapeutic drug monitoring-guided dosing is associated with better event-free survival (EFS), lower transplant-related mortality. But optimal target steady-state concentration (Css) of Bu in children undergoing hematopoietic stem cell transplantation (HSCT) remains unclear. This study aimed to evaluate the relation between Css of Bu and clinical outcomes in children receiving Bu before HSCT. Methods: This study includes 75… Expand
Personalized pharmacokinetic targeting with busulfan in allogeneic hematopoietic stem cell transplantation in infants with acute lymphoblastic leukemia
TLDR
The clinical outcome of engraftment, graft-versus-host disease, adverse events, including sinusoidal obstruction syndrome, and survival did not correlate with the BU PK data, which paradoxically suggests that remaining within this Css range helped minimize transplant-related toxicities, while securing engraftments in infants with MLL-r ALL. Expand
Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children
TLDR
For children with high risk myeloid malignancies receiving an UCBT, first dose Bu pharmacokinetic seems to be a significant prognostic factor, influencing neutrophil and platelet recovery and non-relapse mortality, and reinforcing the importance of Busulfan therapeutic drug monitoring-guided dosing in pediatric HSCT patients, particularly in the context of UCBT. Expand
Therapeutic Drug Monitoring of Busulfan for the Management of Pediatric Patients: Cross-Validation of Methods and Long-Term Performance
Background: Busulfan (Bu) is an alkylating agent used as part of the conditioning regimen in pediatric patients before hematopoietic stem cell transplantation. Despite intravenous (IV) administrationExpand
Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation.
  • J. Ward, M. Kletzel, +4 authors W. Tse
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2015
TLDR
The difference in clinical outcomes between the 2 cohorts supports the conclusion that targeting a higher Bu AUC of 5000 μMol*minute per day for 2 days improves donor engraftment in infants with nonmalignant conditions undergoing RIC HPCT without increasing toxicity. Expand
Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different?
  • P. Mehta, C. Emoto, +7 authors F. Boulad
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2019
TLDR
This is the first and largest report of prospective BU PK in patients with FA undergoing HCT, providing optimal BU target cut off to achieve stable donor engraftment while avoiding excessive toxicity. Expand
Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.
TLDR
The main outcome of interest was event-free survival and improved clinical outcomes are likely to be achieved by targeting the busulfan AUC to 78-101 mg hokinetic model for all indications. Expand
Use of an Oral Busulfan Test Dose in Patients Undergoing Hematopoietic Stem Cell Transplantation Treated With or Without Fludarabine
TLDR
The results suggest that in concomitant administration of FLU and BU during conditioning regimens for HSCT, changes in BU dose should be considered only after the administration of the fifth BU dose. Expand
GSTA1 Genetic Variants and Conditioning Regimen: Missing Key Factors in Dosing Guidelines of Busulfan in Pediatric Hematopoietic Stem Cell Transplantation.
  • T. Nava, M. A. Rezgui, +7 authors H. Bittencourt
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2017
TLDR
It is suggested that GSTA1 diplotypes was a factor that should be included in future population pharmacokinetic models, including similar conditioning regiments, to improve the prediction of Bu exposure after its initial dose and suggest that these factors should be considered in Bu dose prediction in addition to the anthropometric data from patients. Expand
Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning.
  • J. Zao, T. Schechter, +5 authors L. Dupuis
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2015
TLDR
The authors' objective was to describe the AUCs achieved after simulated dosing using available pediatric i.v. busulfan dosing guidelines, and recommend 1 of 3 high-performing guidelines that allow individualization of the targetBusulfan AUC. Expand
Pharmacogenetic aspects of drug metabolizing enzymes in busulfan based conditioning prior to allogenic hematopoietic stem cell transplantation in children.
TLDR
It is hypothesized that some of this variability in BU pharmacokinetics and treatment outcomes, especially the toxicity, might be predicted by genetic variants of enzymes involved in the metabolism of BU. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 51 REFERENCES
Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation.
  • I. Bartelink, R. Bredius, +8 authors J. Boelens
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2009
TLDR
D dose targeting of busulfan to a narrow therapeutic range was found to increase EFS in children, and adding melphalan to optimal bus sulfuran exposure is associated with a high incidence of toxicity. Expand
Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation
TLDR
Targeting Bu Css ranges of 600–900 ng/ml significantly improved the rate of successful engraftment from 74% to 94% and indicates that targeted busulfan dosing optimizes allogeneic engraftedment in children. Expand
Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity
TLDR
It is concluded that, in accordance with previous data, within the observed AUCs no clear relationship was observed between Bu AUC and outcome with respect to toxicity, engraftment and relapse. Expand
Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation
TLDR
It may be possible to improve the outcome of HSCT in pediatric patients receiving the BU/CY regimen through optimization of busulfan CSS and better definition of the contribution of activated cyclophosphamide metabolites to toxicity. Expand
Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results
TLDR
This study demonstrates that a cumulative dosage of 16 mg/kg is associated with higher exposure than expected in infants, and suggests an initial dose of 0.8  mg/kg followed by pharmacokinetically guided dose adjustment. Expand
Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies
TLDR
The feasibility of adjusting the oral BU dose in individual pediatric patients is demonstrated and toxicity associated with BU seemed to be reduced, but the overall regimen-related toxicity (RRT) remains substantial and reflected the effects of all agents used in the preparative regimen. Expand
Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
  • T. Schechter, Y. Finkelstein, +4 authors L. Dupuis
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2007
TLDR
A retrospective pharmacokinetic analysis of i.v. busulfan in children undergoing hematopoietic stem cell transplantation (HSCT) and its relation to transplantation outcomes was conducted and no association was observed betweenBusulfan disposition and development of HVOD in children for whom it was given as part of their conditioning regimen. Expand
Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study
TLDR
A limited sampling strategy based on a Bayesian methodology was developed and validated on an independent dataset: AUCs obtained from one to two samplings were demonstrated to be reliably estimated and no dose adjustment is required in obese patients when using a AIBW- or BSA-based dose calculation. Expand
Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia
TLDR
Pharmacokinetic dosing of BU may be important for prevention of NRM but does not appear to influence the risk of relapse in this largely pediatric population with AML. Expand
Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia.
  • S. Santarone, J. Pidala, +11 authors C. Anasetti
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2011
TLDR
When compared to irradiation-containing regimens, FLU and PK-targeted BU appear safer and similarly effective in controlling ALL, providing a treatment option for adult patients with ALL. Expand
...
1
2
3
4
5
...